Assessing differential application of thromboprophylaxis regimes related to risk of pulmonary embolism and mortality in COVID-19 patients through instrumental variable analysis

Abstract Thrombotic complications are common in Coronavirus disease 2019 (COVID-19) patients, with pulmonary embolism (PE) being the most frequent. Randomised trials have provided inconclusive results on the optimal dosage of thromboprophylaxis in critically ill COVID-19 patients. We utilized data f...

Полное описание

Библиографические подробности

Главные авторы:	Linda Nab, Chantal Visser, Bas C. T. van Bussel, Albertus Beishuizen, Remy H. H. Bemelmans, Hugo ten Cate, F. Nanne Croles, Coen van Guldener, C. Peter C. de Jager, Menno V. Huisman, Marten. R. Nijziel, Pieter W. Kamphuisen, Frederikus A. Klok, Stephanie C. E. Koster, Nuray Kuşadasi, Karina Meijer, Corstiaan A. den Uil, Roger E. G. Schutgens, Frank Stam, Alexander P. J. Vlaar, Eline A. Vlot, Marijke P. M. Linschoten, Folkert W. Asselbergs, Marieke J. H. A. Kruip, Saskia le Cessie, Suzanne C. Cannegieter, Dutch Covid and Thrombosis Coalition & the CAPACITY-COVID collaborative consortium
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Nature Portfolio 2025-03-01
Серии:	Scientific Reports
Предметы:	COVID-19 Heparin Low-molecular-weight Pulmonary embolism Hospital mortality Dose–response relationship
Online-ссылка:	https://doi.org/10.1038/s41598-024-77858-w
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!